NIRAPARIB
Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor used in the treatment of certain types of cancer. It works by interfering with DNA repair mechanisms in cancer cells, ultimately leading to their destruction. NIRAPARIB is a poly (ADP-ribose) polymerase (PARP) inhibitor-Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. -For the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCAmutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
-Patients should be closely monitored for hematologic toxicities, and dose adjustments may be necessary based on individual tolerability. -Niraparib may cause myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); patients should be informed about the potential risks. -Pregnant women should be advised of the potential harm to the fetus, and effective contraception should be used during treatment. -The recommended dosage of Niraparib is typically based on the patient's body weight and blood cell counts. It is important to follow the prescribed dosage regimen provided by the healthcare provider. -Oral; capsule or tablet 100mg, 200mg, 300mg -First-line maintenance treatment of advanced ovarian cancer: -For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken orally once daily. -For patients weighing ?77 kg (?170 lbs) AND a platelet count ?150,000/ mcL, the recommended dosage is 300 mg taken orally once daily. - Maintenance treatment of recurrent germline BRCAmutated -Ovarian cancer: The recommended dosage is 300 mg taken orally once daily.
-Niraparib is contraindicated in patients with a history of severe allergic reactions to any components of the medication. It should also be avoided in individuals with severe hepatic impairment. -Hypersensitivity
-For patients with moderate hepatic impairment, reduce the starting dosage of niraparib to 200 mg once daily Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy:Based on its mechanism of action, NIRAPARIB can cause fetal harm when administered to pregnant women Lactation: Advise a lactating woman not to breastfeed during treatment with NIRAPARIB and for 1 month after receiving the last dose. Elderly: Use with caution.
-Common side effects of Niraparib may include fatigue, nausea, constipation, anemia, and thrombocytopenia. Serious adverse reactions may include hypertension, myelodysplastic syndrome, and acute myeloid leukemia. -Most common adverse reactions in patients who received NIRAPARIB were nausea, thrombocytopenia, anemia, fatigue, constipation, musculoskeletal pain, abdominal pain, vomiting, neutropenia, decreased appetite, leukopenia, insomnia, headache, dyspnea, rash, diarrhea, hypertension, cough, dizziness, acute kidney injury, urinary tract infection, and hypomagnesemia.
Niraparib may interact with drugs that are inhibitors or inducers of CYP3A4 and P-glycoprotein. Co-administration with strong CYP3A4 inducers or inhibitors should be avoided.
